Y. El-Ahmad

发表

Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.

C. Venot, H. Strobel, D. Lesuisse, 2011, Bioorganic & medicinal chemistry letters.

Scalable Synthesis of (R,R)-N,N-Dibenzyl-2-fluorocyclohexan-1-amine with CsF under Hydrogen Bonding Phase-Transfer Catalysis

C. Aubert, V. Gouverneur, V. Certal, 2021, Organic Process Research & Development.

Optimization and Gram-Scale Preparation of S-Trifluoromethyl Sulfoximines and Sulfilimino Iminiums, Powerful Reagents for the Late Stage Introduction of the CF3 Group

V. Certal, Y. El-Ahmad, Guillaume Dagousset, 2020, Organic Process Research & Development.

SYNTHESIS OF 1-OMEGA -(ARYLAMINO)CARBONYLALKYL-4-(BENZOCYCLOALKYL)PIPERAZINES

P. Maillet, E. Laurent, Y. El-Ahmad, 1997 .

Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.

J. Nicolas, C. Lengauer, L. Vincent, 2012, Journal of medicinal chemistry.

Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.

Jean-Pierre Marquette, Magali Mathieu, Thomas Bertrand, 2014, Journal of medicinal chemistry.

A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.

Jean-Pierre Marquette, Magali Mathieu, Thomas Bertrand, 2014, Nature chemical biology.

SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Joon Sang Lee, C. García-echeverría, L. Debussche, 2020, Molecular Cancer Therapeutics.

MOLECULAR CANCER THERAPEUTICS | SMALL MOLECULE THERAPEUTICS SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Joon Sang Lee, L. Debussche, M. Levit, 2020 .

Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors.

M. Mathieu, C. García-echeverría, F. Gay, 2014, Journal of medicinal chemistry.

Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.

M. Mathieu, C. García-echeverría, M. Levit, 2019, Journal of medicinal chemistry.

Abstract 943: SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust antitumor efficacy and limited cross-resistance in ER+ breast cancer

C. García-echeverría, C. Winter, L. Debussche, 2018, Endocrinology.

A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.

M. Mathieu, C. García-echeverría, B. Pasquier, 2014, Nature chemical biology.

Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitors.

J. Nicolas, C. Lengauer, L. Vincent, 2012, Bioorganic & medicinal chemistry letters.